已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Rituximab Therapy for Treatment of Pemphigus in Southeast Asians

医学 美罗华 内科学 危险系数 天疱疮 不利影响 置信区间 胃肠病学 人口 寻常性天疱疮 外科 免疫学 淋巴瘤 环境卫生
作者
Silada Kanokrungsee,Tanaporn Anuntrangsee,Jutamas Tankunakorn,Ploychompoo Srisuwanwattana,Poonkiat Suchonwanit,Kumutnart Chanprapaph
出处
期刊:Drug Design Development and Therapy [Dove Medical Press]
卷期号:Volume 15: 1677-1690 被引量:14
标识
DOI:10.2147/dddt.s306046
摘要

BACKGROUND: Rituximab provides more effective and less adverse effects than the standard dose of corticosteroids, but evidence on its efficacy and safety in the Thai population is lacking. OBJECTIVE: To evaluate the efficacy and safety of rituximab in the treatment of pemphigus and also to determine prognostic factors linked to the treatment outcomes. METHODS: Pemphigus patients who received rituximab from November 2017 to December 2020 were retrospectively reviewed. The outcome was evaluated by using early (end of consolidation phase [ECP]) and late endpoints (complete remission [CR] on/off therapy, immunological remission [IR], and relapse). Adverse events were noted. Prognostic factors associated with remission and relapse were analyzed. RESULTS: Of 53 pemphigus patients, all attained ECP within 1.61 months. Almost 80% achieved CR on therapy within a median time of 6.36 months, while 33.9% reached CR off therapy in 19.74 months. Nearly half had IR within a median time of 6.88 months. Relapse occurred in 33.3% with a median time of 14 months. In multivariate analysis, receiving rituximab within 12 months of disease duration was more likely to achieve CR off therapy and IR (hazard ratio [HR] 3.79; 95% confidence interval [CI] 1.38, 10.42; P = 0.01 and HR 2.74; 95% CI 1.12, 6.69; P = 0.027, respectively), whereas older patients and positive anti-desmoglein 1 levels at the time of CR were predictive indicators for relapse (HR 1.07; 95% CI 1.01, 1.13; P = 0.036 and HR 4.38; 95% CI 1.24, 15.46; P = 0.022, respectively). The treatment-related adverse effects occurred in 33.9%. CONCLUSION: Rituximab is effective and safe in Thai pemphigus patients. Early administration of rituximab was a predictor of clinical and immunological remission. Older age and persistently positive anti-Dsg1 were correlated with disease relapse.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
671完成签到 ,获得积分10
2秒前
水煮电吹风的应助被舒心誉采纳,获得10
2秒前
秋风的应助被浮云采纳,获得20
3秒前
mm发布了新的文献求助30
3秒前
FashionBoy的应助被高兴香彤采纳,获得10
3秒前
人间枝头发布了新的文献求助10
5秒前
粒粒糖发布了新的文献求助10
5秒前
5秒前
KalEl发布了新的文献求助10
5秒前
秋风的应助被heaven采纳,获得10
5秒前
慕青的应助被潇洒的代双采纳,获得10
6秒前
共享精神的应助被渴乐采纳,获得10
7秒前
ZM发布了新的文献求助10
7秒前
7秒前
7秒前
高大橙发布了新的文献求助10
7秒前
7秒前
7秒前
江鳞完成签到,获得积分10
8秒前
8秒前
共享精神的应助被缺口口采纳,获得10
8秒前
9秒前
9秒前
9秒前
NexusExplorer的应助被畅销款采纳,获得10
10秒前
黑球发布了新的文献求助10
11秒前
无情妙菡发布了新的文献求助10
11秒前
哈哈哈哈完成签到,获得积分10
12秒前
无极微光的应助被元宵采纳,获得20
12秒前
魏魏发布了新的文献求助10
13秒前
生动盼兰发布了新的文献求助10
13秒前
wzy发布了新的文献求助10
13秒前
14秒前
渴乐完成签到,获得积分10
14秒前
14秒前
15秒前
情怀的应助被自由的梨愁采纳,获得10
15秒前
chen完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179104
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21806134
捐赠科研通 7774263
什么是DOI,文献DOI怎么找? 3433003
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478643